US Senate kicks off fresh round of drug pricing control legislation
FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space
Novartis culls 10% of pipeline, doubles down on five core therapeutic areas
*please scroll down for all the latest news*
